Krystal Biotech Inc

KRYS is in a Stage 3 distribution phase following a terminal blow-off top, assigning a medium-term Bearish bias. Short-term price remains below declining 9/21 EMAs and is currently pulling back into that resistance zone without a clear rejection signal. Execution is deferred, with trimming opportunities to be considered upon a rejection at the EMA region near the 9/21 EMA zone.

• ↑Net revenue of $116.4M in Q1 2026 (+32% YoY; +9% sequential growth).
• ↑Gross margin of 95%, up from 94% YoY, drives high operational returns.
• ↓Negative earnings yield suggests potential overvaluation risk.